**Curriculum Vitae**

**Douglass W. Forsha, M.D.**

**Office**: Jordan Valley Dermatology Center

3570 West 9000 South, Suite 220

West Jordan, Utah 84088

Phone: (801) 569-1456

Research Direct phone: (801) 316-0266

FAX: (801) 565-7931

Email: dforsha@jvderm.com

**Degrees Earned**

M.D.: Vanderbilt University School of Medicine, Nashville, Tennessee – 1985

B.A. (cum laude): Asian Studies – Brigham Young University, Provo, Utah – 1979

**Education**

Residency: Dermatology – University of Illinois College of Medicine at Chicago – 1986 – 1989

Postgraduate Internship: Internal Medicine – Vanderbilt University and Affiliated Hospitals –

1985 – 1986

Graduate: Vanderbilt University School of Medicine – 1981 – 1985

Undergraduate: Brigham Young University, Provo, Utah – 1973 – 1979

**Professional Memberships**

American Academy of Dermatology

American Medical Association

**Experience**

Jordan Valley Dermatology, West Jordan, Utah – January 2014

Medical Director and Principal Investigator

Founded South Valley Dermatology, West Jordan, Utah – July 1991

Medical Director and Principal Investigator

Dermatology practice at Aiken Dermatology and Skin Cancer Clinic

Aiken, South Carolina – July 1989 – July 1991

**Certification and Licensure**

GCP Certified – Expires September 2020

Medical License – State of Utah (1056010010) – State of Wyoming (8010A)

National Board of Medical Examiners – Diplomate – 1986

**Hospital Privileges**

Intermountain Medical Center, Murray, Utah – Courtesy Staff

Jordan Valley Medical Center, West Jordan, Utah – Active Staff

Pioneer Valley Hospital, West Valley City, Utah – Active Staff

**Co-Author**

Boguniewicz, M., Paller, A. S., Tom, W. L, Lebwohl, M. G., Blumenthal, R. L, Call, R. S., ... Gold, LF.S. (2016). Efficacy and Safety of Crisaborole Topical Ointment, 2%, a Novel, Nonsteroidal, Topical, Anti-Inflammatory, Phosphodiesterase Inhibitor in 2 Phase 3 Studies in Children and Adults with Mild-to-Moderate Atopic Dermatitis. Journal of Allergy and Clinical Immunology, 137(2), AB397. doi:10.1016/ j.jaci.2015.12.1230

Eichenfield, L F., Call, R. S., Forsha, D. W., Fowler, J., Hebert, A. A., Spellman, M., ... Tschen, E. (2017). Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. Journal of the American Academy of Dermatology, 77(4), 641-649.e5. doi:10.1016/j. jaad.2017.06.010

Hebert, A., Glaser, D. A., Green, L, Werschler, W. P., Forsha, D. W., Drew, J., Gopalan, R. & Pariser, D. M. (2018). Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: Post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials. Pediatric Dermatology, 36(1), 89-99. doi:10.1111/pde.13723

Paller, A. S., Tom, W. L, Lebwohl, M. G., Blumenthal, R. L, Boguniewicz, M., Eichenfield, L. F., Call, R. S., ... Hebert, A. A. (2016). Crisaborole topical ointment, 2%: Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. Journal of the American Academy of Dermatology, 75(3), 494-503.e6. doi:10.1016/ j.jaad.2016.05.046

Paller, A. S., Tom, W. L, Lebwohl, M. G., Blumenthal, R. L, Boguniewicz, M., Eichenfield, L S., ... Hebert, A. A. (2017). Crisaborole topical ointment, 2%: A novel, nonsteroidal, topical antiinflammatory, phosphodiesterase 4 inhibitor: results from two phase 3 studies treating children and adult patients with mild to moderate atopic dermatitis. Journal of the American Academy of Dermatology, 76(4), 777. doi:10.1016/j.jad.2016.05.046

Zane, L T., Eichenfield, L F., Call, R. S., Forsha, D. W., Fowler, J. F., Hebert, A. A., ... Tschen, E. H. (2016). Long-term safety of crisaborole topical ointment, 2%, in children and adults with mild-to-moderate atopic dermatitis. The Journal of Immunology, 196(1 Supplement), 191.28. Retrieved from http://www.jimmunol.org/content/196/1\_Supplement/191.28

Zane, L T., Paller, A. S., Tom, W. L, Lebwohl, M. G., Blumenthal, R. L, Boguniewicz, M., ... Simpson, E.L (2016). Two phase 3 study results of children and adults with mild-to-moderate atopic dermatitis treated with Crisaborole Topical Ointment, 2%, a novel, nonsteroidal, topical, anti-inflammatory, phosphodiesterase 4 inhibitor. The Journal of Immunology, 196(1 Supplement), 191.26. Retrieved from http://www.jimmunol.org/content/196/1\_Supplement/191.26

**Poster Sessions**

American Academy of Dermatology (AAD) Annual Meeting  
March 4, 2017  
Orlando, Florida

[Crisaborole topical ointment, 2%: A novel, nonsteroidal, topical anti-inflammatory, phosphodiesterase 4 inhibitor: Results from two phase 3 studies treating children, adults with atopic dermatitis](https://www.medconferencecoverage.com/conference-abstract.cfm/60868/?conf_id=239920)

Summary: In these two phase 3 clinical trials, researchers evaluated the efficacy and safety of crisaborole topical ointment, 2%, in children and adults with mild to moderate atopic dermatitis (AD), and concluded that this ointment had favorable efficacy and safety in patients as young as 2 years old with mild to moderate AD.

MauiDerm   
January 25-29, 2016   
Maui, Hawaii  
Results from two Phase 3 studies in children and adults with mild-to-moderate Atopic Dermatitis treated withi Crisaborole Topical Ointment, 2%, a novel nonsteroidal, topical anti-inflammatory, Phosphodiesterase 4 inhibitor  
Summary: Crisaborole Topical Ointment, 2%, demonstrated favorable efficacy and safety in two large Phase 3 studies and may represent a safe and efficacious treatment for patient as young as two years with mild-to-moderate AD.

16th Annual Las Vegas Dermatology Seminar: Scientific Abstract,

November 5-7, 2015

Las Vegas, Nevada

PA-11: Crisaborole topical ointment 2%, a novel nonsteroidal, topical, anti-inflammatory, phosphodiesterase 4 inhibitor: results in children and adults with mild-to-moderate atopic dermatitis from two phase 3 studies

Conclusion: in 2 large Phase 3 studies, favorable efficacy and safety was demonstrated for Crisaborole Topical Ointment, 2%. It may represent a novel, safe, and efficacious treatment for patients as young as 2 years with mild-to-moderate AD.

**Other Activities**

Chief Organist at church in Aiken, South Carolina

Lived in Thailand 1974 – 1976 – Speak fluent Thai

Member of the Mormon Tabernacle Choir, Salt Lake City, Utah – 1973 – 1974

Enjoy snow skiing, swimming and racquetball

**Previous and Ongoing Research Experience**

**Douglass William Forsha, M.D.**

A Phase 3, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Maintenance Treatment and Flare Reduction with XXX Ointment, 2%, Once Daily Over 52 Weeks in Pediatric and Adult Participants (Ages 2 Years and Older) with Mild-to-Moderate Atopic Dermatitis, who Responded to Twice Daily XXX Ointment, 2%, Treatment

Dec 2019/Current

**SPONSOR:** Pfizer

A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of XXX Cream 0.3% Administered QD in Subjects with Chronic Plaque Psoriasis

Feb 2020/Current

**SPONSOR:** Arcutis Inc.

A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of XXX Cream 0.3% in Subjects with Chronic Plaque Psoriasis who have Completed Preceding Studies XXX-301 or XXX-302

Feb 2020/Current

**SPONSOR:** Arcutis Inc.

A Randomized, Double-Blind, Placebo-Controlled, Efficacy Study of the Neurokonin-Receptor Antagonist XXX in Patients with Atopic Dermatitis

Nov 2019/Current

**SPONSOR:** Vanda Pharmaceuticals Inc.

A Phase 3 Efficacy and Safety Study of XXX for the Treatment of Plaque Psoriasis in Adults

July 2019/Current

**SPONSOR:** Dermavant Sciences, Inc

A Long-Term, Open-Label, Extension Study to Evaluate the Safety and Efficacy of XXX Cream, 1% for the Treatment of Plaque Psoriasis in Adults

July 2019/Current

**SPONSOR:** Dermavant Sciences, Inc

A Phase 3 Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-Centered Study Investigating the Efficacy and Safety of XXX and XXX in Comparison with Placebo in Adult Subjects on Background Topical Therapy, with Moderate to Severe Atopic Dermatitis

May 2019/Current

**SPONSOR:** Pfizer

A Phase 3 Multi-Center, Long-Term Extension Study Investigating the Efficacy and Safety of XXX, With or Without Topical Medications, Administered to Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis May 2019/Current

**SPONSOR:** Pfizer

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XXX in Pediatric Subject form 6 Through 17 years of Age with Moderate to Severe Plaque Psoriasis.

Dec 2018/ Current

**SPONSOR:** Celgene

A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of xxx Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis.

Feb 2019/ Current

**SPONSOR:** Incyte

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multicenter dose-ranging study to assess the safety and efficacy of multiple oral XXX doses in patients with moderate to severe atopic dermatitis (ZEST trial).

Dec 2018/Current

**SPONSOR:** Novartis

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy Study of the Neurokinin-1 Receptor Antagonist XXX in Subject with Atopic Dermatitis.

July 2018/Current

**SPONSOR:** Vanda

A Phase 3 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study of XXX in the Treatment of Acne Vulgaris

Mar 2019/Current

**SPONSOR:** Sol-Gel Technologies, Ltd

A Phase 2, A Pilot Evaluation of a Novel Therapy (Drug and Device) to Promote Hair Growth in Androgenetic Alopecia (AGA): A Prospective, Multicenter, Randomized Study.

Mar 2018/Current

**SPONSOR:** Follica

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of XXX in Adult Patients with Moderate to Severe Atopic Dermatitis

May 2018/Sept 2019

**SPONSOR**: Eli Lilly and Company

A Phase 4, Multicenter Open-label Safety Study of XXX Ointment, 2% in Children Aged 3 months to less than 24 months with Mild to Moderate Atopic Dermatitis

Jan 2018/May 2019

**SPONSOR**: Pfizer

A Multicenter, Double-Blind, Nontreatment, Long-term, Follow-up Study of Subjects Who Completed Clinical Studies 755.1100\_FA, 810.1100\_FA, or 1064.1100\_FA of a Topical XXX Solution Followed by Laser for the Treatment of Facial Acne Vulgaris

Device

Phase Pivotal

May 2018/Mar 2019

**SPONSOR**: Sienna

Clinical Investigation of a Topical XXX Solution Followed by 755 nm Laser for the Treatment of Acne Vulgaris in Facial Areas of Subjects

Device

Phase Pivotal

Jan 2018/Mar 2019

**SPONSOR**: Sienna

A Double-Blind Clinical Investigation of the Efficacy and Safety of XXX Used in Conjunction With Laser for Light-Hair Removal

Device

Phase Pivotal

August 2017/Sep 2019

**SPONSOR**: Sienna

A Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2 Arm, Parallel Group Study Comparing the Safety and Efficacy of XXX Lotion and XXX Vehicle Lotion in the Treatment of Acne Vulgaris

Phase III

July 2017/July 2018

**SPONSOR**: Valeant/CuTech

Evaluation of efficacy, duration of remission and safety of a light and occlusive patch therapy for plaque psoriasis.

Device

Dec 2016/ Oct 2018

**SPONSOR:** Luma Therapeutics, Inc.

A Randomized, Prospective, Multicenter, Double Blind, Parallel Assignment, Placebo Controlled Bioequivalence Study of XXX Cream, 1% and XXX Cream, 1% in Patients with Mild to Moderate Atopic Dermatitis.

Dec 2016/Aug 2017

**SPONSOR:** DPT Laboratories, Ltd., a Division of Mylan

A Randomized, Double-Blind Study to Compare the Efficacy, Safety and Long-Term Safety of Topical Administration of XXX for 1 Year in the Treatment of Moderate-to-Severe Acne Vulgaris, Study XXX

Jun 2016/Jan 2018

**SPONSOR:** Foamix Pharmaceutials

A randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi-Site Phase 2b Clinical Study to Assess the Efficacy, Safety and Tolerability of 8 –week Regimens XXX, 10% Topical Solution (Taro Pharmaceutials, USA, Inc.) in Patients with Mild to Moderate Onychomycosis

Mar 2016/Mar 2018

**SPONSOR:** Taro Pharmaceutials, USA

XXX versus placebo In a Multicenter randomized double-blind study in patients with Moderate to severe chronic plaque psoriasis evaluating the efficacy and safety with randomized withdrawal and re-treatment

Mar 2016/May 2016

**SPONSOR:** Boehringer Ingelheim

An Open-label Study to Evaluate the Safety and Tolerability of XXX topical solution, 5% in the Treatment of Onychomycosis of the Toenail in Pediatric Patients Aged 6 to 16 Years and 11 Months.

March 2016/Nov 2017

**SPONSOR:** Anacor

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of XXX in Treatment-Resistant Pruritus Associated with Atopic Dermatitis

Mar 2016/Oct 2017

**SPONSOR:** Vanda Pharmaceuticals, Inc.

A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis

Nov 2015/Feb 2017

**SPONSOR:** Dow Pharmaceutical Sciences, a Division of Valeant Pharmaceuticals North America, LLC

A Randomized, Double-Blind, Parallel-Design, Muti-Site Study to Evaluate the Therapeutic Equivalence of XXX XXX Gel 3% (Taro Pharmaceuticals USA, Inc.) Compared to XXX 3% Gel (XXX XXX 3% w/w; Almirall, S. A.) in the Treatment of Actinic KeratosisBioequivalance study

Jul 2015/Apr 2016

**SPONSOR:** Novum

A Phase 3, Randomized, Double-blind, Vehicle-Controlled Efficacy and Safety Study of XXX in Subjects with Axillary Hyperhidrosis

Aug 2015/July 2016

**SPONSOR:** Dermira

An Open-Label Study Assessing Long-Term Safety of XXX in Subjects with Primary Axillary Hyperhidrosis

Aug 2015/ Mar 2017

**SPONSOR:** Dermira

A Multi-Center, Double-Blind, Randomized Vehicle-Controlled, Parallel- Group Study to Compare XXX XXX Cream, 5% with XXX (XXX) Cream 5%, and both Active Treatments to a Vehicle Control in Treatment of Recurrent Herpes Simplex Labialis

Bioequivalance study

Nov 2014/May 2016

**SPONSOR:** Perrigo

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous XXX [300 mg] as assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 weeks of Treatment, Compared to Placebo, and to Assess Safety and Tolerability up to 24 Weeks in Adult Subjects with Moderate to Severe Scalp Psoriasis Phase lll

Dec 2014/May 2016

**SPONSOR:** Novartis

A Prospective, Observational Study to Estimate the Proportion of Subjects with Plaque Psoriasis who Achieve Complete Clearance On Biologics

May 2014/Mar 2016

**SPONSOR:** Amgen

A Randomized, Multicenter, Double Blind, Phase III, Placebo-controlled Study to Evaluate the Efficacy and Safety of 1.5mg/kg per Day of XXX Compared to Placebo in the Treatment of Acne Vulgaris

Nov 2014/Feb 2017

**SPONSOR:** Warner/Chilcott/Allergan

A Multi-Center Open-Label Evaluation of the Safety of XXX Tablets in the Treatment of Acne Vulgaris

May 2015/Sept 2016

**SPONSOR:** Warner/Chilcott/Allergan

A Multicenter, Randomized, Double Blind, Parallel Group, Vehicle Controlled Study of the Safety and Efficacy of XXX 3mcg/g Ointment Applied Twice Daily for 8 Weeks in Pediatric Subjects (2 to 12 years of age) with Mild to Moderate Plaque Psoriasis

Phase lV

Jun 2014/Apr 2016

**SPONSOR:** Galderma

XXX, A Phase 2, Randomized, Double-Blind, Multicenter, Parallel Group, Placebo Controlled Study to Assess the Efficacy and Safety of 3 Dose Levels of XXX in Subjects with Chronic Plaque-type Psoriasis

Aug 2014/Sep 2015

**SPONSOR:** XenoPort

A Randomized, Double-blind, Placebo Controlled Study to Demonstrate the Efficacy and Long Term Safety of XXX in Adult Patients with Moderate to Severe Atopic Dermatitis

Phase 3

Nov 2014/May 2015

**SPONSOR:** Regeneron

A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of XXX Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis

Phase lll

Apr 2014/Aug 2015

**SPONSOR:** Anacor

A Multicenter, Open-Label Study of the Long-Term Safety of XXX Topical Ointment, 2% in the Treatment of Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis

Phase lll

Jun 2014/November 2015

**SPONSOR:** Anacor

A Safety and Efficacy Study to Compare XXX Dermal Gel with Vehicle Control in Patients with Acne Vulgaris

Phase lll

Feb 2014/Dec 2014

**SPONSOR:** Allergan

A Phase IV, Open-Labeled, Photographic Study with Acne Patients with Severe Recalcitrant Nodular Treated with XXX (XXX) Capsules

Feb 2014/May 2015

**SPONSOR:** Ranbaxy

A Phase IV, Open-Labeled, Photographic Study with Acne Patients with Severe Recalcitrant Nodular Treated with XXX (XXX) Capsules

May 2015/Apr 2018

**SPONSOR:** Ranbaxy

A 52 –Week, Phase III, Randomized, Active Comparator and Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous of XXX XXX/XXX, Followed by an Optional Long-Term Safety Extension Study, in Subjects with Moderate-to-Severe Chronic Plaque Psoriasis

Jul 2013/Current

**SPONSOR:** Merck

A 264-week Multlicenter, Randomized, Double-blind, Placebo-Controlled Study Comparing the Efficacy and Safety of XXX to XXX and Placebo in Patients with Moderate-to-Severe Plaque Psoriasis with a Long-term Extension Period

Phase lll Biologic

Sep 2012/Current

**SPONSOR:** Eli Lilly

A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of XXX Capsules in Adult Subjects with Atopic Dermatitis

Phase ll

Aug 2013/Apr 2014

**SPONSOR:** Asubio

A Phase III Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of XXX Compared with Placebo and XXX in Subjects with Moderate to Severe Plaque Psoriasis

Biologic

Nov 2012/Mar 2016

**SPONSOR:** Amgen

Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study Comparing XXX XXX Gel 3% (XXX) to XXX (XXX XXX) Gel 3% (XXX XXX) in the Treatment of Actinic Keratosis.

Mar 2013/Sep 2013

**SPONSOR:** Novum

A Randomized, Double-blind, Placebo-controlled, Multiple-site Study Comparing XXX Topical Gel 1% (XXX XXX XXX) to XXX (XXX gel) 1% (XXX) in the Treatment of Moderate-to-Severe Rosacea

Phase lll

Aug 2011/May 2012

**SPONSOR:** Novum

A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study of XXX in the Treatment of Recurrent Herpes Labialis

Phase lll

Apr 2011/Jan 2012

**SPONSOR:** NanoBio Corporation

A Phase 2, Multicenter, Double-Blind, Dose-Ranging Study to Evaluate XXX Versus Placebo in the Treatment of Severe Acne Vulgaris With Nodules

Sep 2010/Dec 2011

**SPONSOR:** Dow

Phase III Study Evaluating XXX Cream 5% Compared to XXX 5% Cream in Patients with Actinic Keratosis

Feb 2009/Dec 2009

**SPONSOR:** Novum

Phase IV Study Evaluating XXX Emulsion in the Clinic When Used as Monotherapy for Atopic Dermatitis. Completed March 2010.

**SPONSOR:**Promius Pharma

A Phase 4, Open-Label, Multicenter, Community-based, 12-Week Trial Assessment of Effectiveness, Safety, and Subject Satisfaction With XXX® [XXX, USP] Capsules 40 mg (30 mg Immediate Release & 10 mg Delayed Release Beads) When Used as Monotherapy or as Add-On Therapy to Existing Topical Regimens for the Treatment of Rosacea

April 2009/Nov 2009

**SPONSOR:** Galderma

A Phase II, Multi-Center, Double-Blind, Randomized, Dose-ranging Study to Evaluate XXX Versus Placebo in the Treatment of Severe Acne Vulgaris with Nodules

Mar 2008/Jul 2009

**SPONSOR:** Dow

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of 2 Doses of XXX (400 mg BID and 800 mg BID) in Patients With Atopic Dermatitis

Phase ll

May 2008/Dec 2009

**SPONSOR:** Shiongi USA

A Follow-up Study to Evaluate Sustained Clearance Rates of Actinic Keratoses up to One Year after Completion of Studies XXX, XXX, XXX, and XXX

May 2008/Oct 2009

**SPONSOR:** Graceway Pharmaceuticals

A Phase 3, Randomized, Double-blinded, Placebo-controlled, Multicenter, Efficacy and Safety Study of Six Weeks of Treatment With Imiquimod Creams for Actinic Keratoses

Jan 2008/Aug 2008

**SPONSOR:** Graceway Pharmaceuticals

A Multi-Center, Randomized, Double-Blind, Active-Control Clinical Triall to Determine the Effects of XXX XXX Modified Release Capsules, 40mg (COL-101) Administered Once Daily in Conjunction with XXX (XXX topical gel, 1%) vs XXX XXX Immediate-Release Capsules, 100mg Administered Once Daily in Conjunction with XXX (XXX topical gel, 1%) in Patients with Moderate to Severe Rosacea

Feb 2007/Jan 2008

**SPONSOR:** CollaGenex Pharmaceuticals

Observational Post-marketing Safety Surveillance Registry of XXX (XXX) for the Treatment of Psoriasis.

May 2006/Feb 2013

**SPONSOR:** Amgen

A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study of XXX in the Treatment of Recurrent Herpes Labialis

May 2011/Apr 2012

**SPONSOR:** NanoBio Corporation

The Safety, Pharmacokinetics and Efficacy of XXX, 0.1%, 0.3%, 0.5% in Subjects with Recurrent Herpes Labialis.

Feb 2007/Dec 2007

**SPONSOR:** NanoBio Corporation

A Phase III Randomized, Evaluator-Blind, Parallel Group Study of the Safety and Efficacy of XXX Tablets, XXX Capsules and Placebo in the Treatment of Onychomycosis of the Toenail

Dec 2006/Jan 2009

**SPONSOR:** Barrier Therapeutics

Open-label, Community Based, Phase 4 Study to Assess Facial Acne Improvement with Use of XXX (XXX gel) Microsphere 0.04% in a Pump Dispenser.

Dec 2006/Aug 2007

**SPONSOR:** Johnson & Johnson

Phase III Study of the Safety and Efficacy Evaluation of XXX Gel, 0.05%, versus XXX Gel Vehicle in the Treatment of Mild-to-Moderate Acne Vulgaris. Ages 10 and older

2005

**SPONSOR:** Healthpoint

Phase IV Trial of XXX Gel for Moderate-to-Moderately Severe Facial Acne

2005

**SPONSOR:** Galderma

XXX vs. XXX Topical Gel for the Treatment of Acne Vulgaris

2005

**SPONSOR:** Medicis Pharmaceutical Corp

52-week Open-label Study of the Safety of XXX XXX 2% Topical Gel in the Treatment of Seb­or­rheic Dermatitis. First in nation asked to enroll

2004-2005

**SPONSOR:** Barrier Therapeutics, Inc

Double-blind, Randomized, Vehicle-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of a Topical Gel Product Containing XXX XXX 2% in the Treatment of Seborrheic Dermatitis

2004

**SPONSOR:** Barrier Therapeutics, Inc

XXX in a Three-stage Dose-escalating Study to Assess Efficacy and Safety for the Treatment of Common Warts in Adults

2004

**SPONSOR:** 3M Pharmaceuticals

XXX for the Treatment of Menstrual Cycles in Women with Mild-to-Moderate Acne Vulgaris

2003

**SPONSOR:** Berlex

A Phase II, Randomized, Vehicle-Controlled, Double-Blind, Multi-Center Study to Evaluate Safety and Efficacy of XXX XXX 1.25% and 2.5% Acne Solutions Applied Topically for 12 Weeks to Subjects With Acne Vulgaris

Jan 2003/Sep 2003

**SPONSOR:** Micrologix BioTech

XXX XXX Pulse-dosing as Treatment of Onychomycosis of the Toenails

2002

**SPONSOR:** Novartis

15% XXX XXX Cream vs. Vehicle Cream as Topical Treatment for Mild-to-Moderate Acne of the Face

2002

**SPONSOR:** Berlex Corporation

Topical Patch Application of XXX for Treatment of Onychomycosis

2001-2002

**SPONSOR:** Watson Pharmaceuticals

XXX XXX vs. XXX in the Treatment of Uncomplicated Skin and Skin Structure Infections

2000

**SPONSOR:** Bayer Corporation

XXX Cream vs. Vehicle Cream in the Treatment of Plantar Tinea Pedis

2000

**SPONSOR:**Schering-Plough

XXX vs. Placebo in the Treatment of Patients with Moderate Acne

1999

**SPONSOR:**Wyeth-Ayerst Laboratories

XXX XXX vs. XXX XXX in the Treatment of Patients with Uncomplicated Skin or Skin Structure Infections

1998

**SPONSOR:** Tap Holdings, Inc.

Transdermal Delivery of Phenobarbital in Neonates. Manipal, India

1988-1989

Efficacy and Safety of 2% Topical XXX Solution for the Treatment of Male Pattern Alopecia. University of Illinois College of Medicine, Department of Dermatology

1986-1987

Immunohistochemical Staining for EGF Receptors in Nonmalignant Dermatoses with Lloyd E. King, Jr., M.D., Professor in Chief, Division of Dermatology, Vanderbilt University School of Medicine, Nashville, Tennessee

1983-1984